The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.

AstraZeneca has announced the Positive high-level results from the Phase III KALOS and LOGOS trials in patients with ...

AstraZeneca’s fixed-dose triple-combination therapy, Breztri meets primary endpoints in KALOS & LOGOS phase III trials in asthma: Cambridge, UK Saturday, May 3, 2025, 10:00 Hrs ...

AstraZeneca (LSE:AZN) recently announced phase III trial results for Breztri Aerosphere, its triple-combination asthma ...

The replicate confirmatory KALOS and LOGOS trials evaluated BGF in participants with severe asthma inadequately controlled with standard of care.

The FDA pushed back its decision date on Cytokinetics’ heart drug, while AstraZeneca got Phase 3 results that could help it ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

Anglo-Swedish pharma major AstraZeneca has presented positive top-line results from the Phase III KALOS and LOGOS trials in ...

Positive results from the Phase III KALOS and LOGOS trials show that AstraZeneca's Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumar ...

The Department of Justice announced a lawsuit against three of the largest insurance companies -- Aetna, Elevance Health, and ...

AstraZeneca said on Friday that the full results from the two trials will be shared with regulatory authorities and presented ...

AstraZeneca's three-drug inhaler Breztri Aerosphere has shown efficacy for uncontrolled asthma in a pair of phase 3 trials ...